

AERAS ASIA

Of the estimated 9.6 million people who developed tuberculosis (TB) in 2014, more than half (58%) were in the South-East Asia and Western Pacific Regions, with India, Indonesia, and China alone accounting for 43% of the world's total TB cases.¹

TUBERCULOSIS IN ASIA: A REGION UNDER THREAT

Multidrug-resistant TB (MDR-TB), deadly and far more expensive to treat, is on the rise, with nearly 170,000 estimated new cases in the region in 2014. Eight of the world's 22 highest TB burden countries are located in the Asia-Pacific region.¹

In South East Asia as in most of the world, TB incidence rates are broadly associated with poverty and limited public health infrastructure. Yet in other parts of Asia, such as China, Japan and Korea, the growing elderly population is also expected to make a significant contribution to TB incidence rates over the coming years. A particular concern for this region is its vast and mobile population, which may facilitate TB transmission and complicate diagnosis and treatment.² TB is a threat that the Asia-Pacific region cannot afford to ignore.



SUPPORTING SOLUTIONS TO TB IN ASIA

- TB has no borders. By supporting TB R&D, donors in Asia help address a public health priority in their own region, as well as around the world.
- Asian countries are increasing their global economic footprint and are taking responsibility for helping to eliminate poverty and provide security and equal access to public health resources.
- Asia has a powerful global presence and can be an effective, influential international public health partner.
- Fighting TB in the Asia-Pacific region has health and economic benefits that extend across the world.

By contributing to solutions to TB in Asia, donors can see the direct impact of their support in the region and beyond.

ASIA'S URGENT NEED FOR TB VACCINES

New vaccines are at the center of future TB elimination efforts. A vaccine that prevents adolescents and adults from developing and transmitting the disease would be a highly cost-effective tool in mitigating this epidemic and preventing the spread of both drug-resistant and drug-sensitive TB.

ABOUT AERAS


Aeras is a nonprofit, global organization advancing the development of new tuberculosis vaccines for the world, in partnership with the public and private sector including, for example, biotech, pharmaceutical, and academic organizations. Serving as a critical translational bridge from the bench to the field, Aeras has sponsored and conducted over 30 clinical vaccine trials enrolling thousands of subjects in countries around the world, and is a key partner in several active clinical development programs.

AERAS ASIA: REGIONAL FOCUS, GLOBAL NETWORK

With our language, cultural and political expertise, Aeras Asia helps key regional stakeholders understand the landscape of TB. We connect policy makers, advocates, research organizations, governments, donors, academic institutions, industry, healthcare workers, and others throughout the region.

Taking a direct role in epidemiology and clinical research projects, Aeras is advancing TB science, building capacity, strengthening partnerships and advancing a diverse portfolio of TB vaccine candidates through the R&D pipeline.

Estimated TB incidence rates, 2014



KEY ACTIVITIES IN ASIA

Aeras Asia takes an active role in TB research around the region. Some of our most recent efforts include:

- Prospective cohort study of TB recurrence in 70 districts throughout Vietnam, in partnership with Australia's Woolcock Institute of Medical Research
- Developing new mucosal TB vaccines in collaboration with Japan's National Institute of Biomedical Innovation and Create Vaccine Co., Ltd.
- Conducting TB prevalence surveys at two sites in China, in conjunction with China CDC and Fudan University
- Comprehensive TB vaccine development, from discovery, to pre-clinical and clinical research

BUILDING UPON PROGRESS

The Aeras Asia office, located in Beijing, China, is geographically positioned to help coordinate and strengthen regional TB efforts, fill critical gaps and improve R&D efficiency. Using diverse outlets such as print, video and social media channels, Aeras Asia promotes the urgent need for TB vaccines and advocates for increased political will to support regional efforts. We also assist stakeholders with meeting international R&D expectations and



regulatory processes. Committed, experienced and engaged, Aeras Asia is a key regional leader across the spectrum of TB vaccines. Aeras is dedicated to ensuring that effective TB vaccines are available to those who need them most.

SUPPORTERS

Aeras receives funding from the Bill & Melinda Gates Foundation, the Global Health Innovative Technology Fund (GHIT) and a range of other governments and organizations.

BILL & MELINDA
GATES foundation

GHIT Fund
Global Health Innovative Technology Fund

CONTACT AERAS ASIA

14th Floor A Tower
Pacific Century Place
Room 26
2A Workers Stadium Road North
Chaoyang District Beijing 100027
P.R. China
P: +86 10 65 876 980
F: +86 10 65 391 060

REFERENCES

1. Global Tuberculosis Report. WHO, 2015.
2. Vermund, S.H. and Yamamoto, N. Tuberculosis. 2007; 87: S18-S25